Once shortages ended earlier in 2025, mass compounding should have stopped too
Tirzepatide delays gastric emptying, and Zepbound trials reported belching in 4% to 5% of dose groups versus 1% with placebo
We would also like to thank the Genomics Research Center (GRC), the Histology, Biochemistry, and Molecular Imaging (HBMI) Core at the Center for Musculoskeletal Research (CMSR), and the Center for Advanced Research Technologies (CART) at URMC, the Bauer Core Facility at Harvard University, and Proteomics/Metabolomics Core at Moffitt Cancer Center, which is funded in part by Moffitts Cancer Center Support Grant (P30CA076292)
Dysbiosis in the gut microbiota promotes inflammation, insulin resistance and metabolic dysfunction through multiple pathways, including the production of short-chain fatty acids (SCFAs) and endotoxins such as lipopolysaccharides (LPS)